Madden Securities’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Madden Securities’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,000	Closed	-$2.14M	–	94
2023 Q2	$2.14M	Sell	21,000 -2,708	-11%	-$256K	1.1%	29
2023 Q1	$2.16M	Hold	23,708	–	–	1.14%	28
2022 Q4	$901K	Hold	23,708	–	–	0.47%	46
2022 Q3	$596K	Sell	23,708 -60	-0.3%	-$1.66K	0.36%	57
2022 Q2	$722K	Hold	23,768	–	–	0.4%	56
2022 Q1	$779K	Sell	23,768 -15,544	-40%	-$461K	0.35%	58
2021 Q4	$1.04M	Buy	39,312 +6,185	+19%	+$479K	0.49%	56
2021 Q3	$3.33M	Sell	33,127 -1,675	-5%	-$196K	1.8%	18
2021 Q2	$4.93M	Buy	34,802 +15	+0%	+$1.69K	2.57%	6
2021 Q1	$3.47M	Sell	34,787 -365	-1%	-$42.6K	2.03%	12
2020 Q4	$4.34M	Sell	35,152 -8,775	-20%	-$1.15M	2.8%	5
2020 Q3	$4.28M	Buy	43,927 +575	+1%	+$71.8K	3.18%	4
2020 Q2	$6.76M	Buy	+43,352	New	+$6.59M	6.02%	2
2019 Q4	$8.83M	Buy	+43,199	New	+$7.88M	8.86%	1

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Madden Securities's RETA Position: Q3 2023 in Review

Madden Securities sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 21,000 shares — an estimated $2.14M sold.

Madden Securities first reported a position in RETA in Q4 2019 and held it in 14 quarters. The position peaked at $8.83M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Madden Securities reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Madden Securities sold 21,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.14M.
Madden Securities first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 14 quarters.
Madden Securities's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.83M in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Madden Securities's 13F filing for Q3 2023, filed 10 Oct 2023.